Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1574090 | 1.00 | CCKBR (0.82) | CCKBRCCKAR | |
| Hydrochloric Acid SCHEMBL8610035 | 0.99 | CCKBR (0.81) | CCKBRCCKAR | |
| SCHEMBL1574573 | 0.94 | CCKBR (0.80) | CCKBRCCKAR | |
| SCHEMBL1574574 | 0.94 | CCKBR (0.80) | CCKBRCCKAR | |
| SCHEMBL1574150 | 0.93 | CCKBR (0.77) | CCKBRCCKAR | |
| SCHEMBL1574148 | 0.93 | CCKBR (0.77) | CCKBRCCKAR | |
| SCHEMBL1574375 | 0.93 | CCKBR (0.80) | CCKBRCCKAR | |
| SCHEMBL1574377 | 0.93 | CCKBR (0.80) | CCKBRCCKAR | |
| SCHEMBL1387652 | 0.92 | CCKBR (0.69) | CCKBRCCKAR | |
| SCHEMBL1387654 | 0.92 | CCKBR (0.69) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1342719-B1 | Benzodiazepine derivatives useful as CCK-Receptor Antagonists | FERRING BV (NL) | 2011-04-13 | — | — | EP | claimed |
| EP-1342719-A1 | Benzodiazepine derivatives useful as CCK-Receptor Antagonists | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-09-10 | — | — | EP | claimed |
| US-5962451-A | GASTROINTESTINAL DISORDERS; ANTIULCER AGENT; ANTICANCER AGENTS; SIDE-EFFECT REDUCTION | FERRING BV (NL) | 1999-10-05 | — | — | US | claimed |
| US-5688943-A | CHOLECYSTOKININ ANTAGONIST; ANTIULCER AGENTS; PSYCHOLOGICAL DRUGS; ANXIOLYTIC AGENTS; CONTROLLING APPETITE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-18 | — | — | US | claimed |
| EP-1342719-B1 | Benzodiazepine derivatives useful as CCK-Receptor Antagonists | FERRING BV (NL) | 2011-04-13 | — | — | EP | disclosed |
| US-20040138207-A1 | Anticancer agents; side effect reduction | ASTELLAS PHARMA INC. (JP) | 2004-07-15 | — | — | US | disclosed |
| EP-1391203-A1 | ANTITUMOR AGENTS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-02-25 | — | — | EP | disclosed |
| EP-1342719-A1 | Benzodiazepine derivatives useful as CCK-Receptor Antagonists | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-5962451-A | GASTROINTESTINAL DISORDERS; ANTIULCER AGENT; ANTICANCER AGENTS; SIDE-EFFECT REDUCTION | FERRING BV (NL) | 1999-10-05 | — | — | US | disclosed |
| US-5688943-A | CHOLECYSTOKININ ANTAGONIST; ANTIULCER AGENTS; PSYCHOLOGICAL DRUGS; ANXIOLYTIC AGENTS; CONTROLLING APPETITE | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1997-11-18 | — | — | US | disclosed |
| EP-0628033-A1 | BENZODIAZEPIN DERIVATIVES USEFUL AS CCK-RECEPTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1994-12-14 | — | — | EP | disclosed |
| WO-1993016999-A1 | BENZODIAZEPIN DERIVATIVES USEFUL AS CCK-RECEPTOR ANTAGONISTS | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138207-A1 | Anticancer agents; side effect reduction | MKI67, TPMT, PBRM1 | CCKBR 39/4885CCKAR 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.